{
    "clinical_study": {
        "@rank": "109390", 
        "acronym": "Symplicity AF", 
        "arm_group": [
            {
                "arm_group_label": "Cryoablation only", 
                "arm_group_type": "Active Comparator", 
                "description": "Pulmonary vein isolation"
            }, 
            {
                "arm_group_label": "Cryoablation and renal nerve denervation", 
                "arm_group_type": "Experimental", 
                "description": "Pulmonary vein isolation plus renal never denervation"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this clinical study is to evaluate the feasibility of performing both renal\n      nerve denervation and pulmonary vein isolation on the same patient with the intent of\n      characterizing both safety and effectiveness in a paroxysmal atrial fibrillation population\n      with hypertension.  To assess safety, the study will measure the occurrence of a composite\n      safety endpoint and, to assess effectiveness, the study will measure freedom of chronic\n      treatment failure through a minimum of six months of follow-up."
        }, 
        "brief_title": "Renal Nerve Denervation in Patients With Hypertension and Paroxysmal Atrial Fibrillation", 
        "condition": [
            "Atrial Fibrillation", 
            "Hypertension"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Atrial Fibrillation", 
                "Hypertension"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Drug refractory recurrent symptomatic paroxysmal atrial fibrillation.  Drug\n             refractory is defined as:  failed (drug is ineffective or patient is intolerant) at\n             least one Class I or III anti-arrhythmic drug.\n\n          -  Office-based systolic blood pressure of \u2265150 mm Hg based on average of three blood\n             pressure readings despite treatment with 2 or more antihypertensive medications of\n             different classes (one of these must be a diuretic) at highest labeled dose according\n             to the medication's labeling, highest usual dose per clinical guidelines (i.e., JNC-7\n             Guidelines), highest tolerated dose or highest appropriate dose for the subject per\n             the Principal Investigator's best clinical judgment.\n\n          -  Ambulatory Blood Pressure Monitoring 24 hour average systolic blood pressure \u2265135\n             mmHg.\n\n          -  Age 18 years to 80 years old.\n\n          -  Willing to give informed consent and agree to all study procedures, and is competent\n             and willing to provide written, informed consent to participate in this clinical\n             study.\n\n        Exclusion Criteria:\n\n          -  Active systemic infection\n\n          -  Condition where manipulation of the catheter within the heart would be unsafe (e.g.\n             intracardiac mural thrombus).\n\n          -  Cryoglobulinemia\n\n          -  One or more pulmonary vein stents\n\n          -  Type I Diabetes\n\n          -  NYHA Class IV heart failure with in the past 6 months\n\n          -  Renal artery anatomy that is ineligible for treatment including: a) Lacks at least\n             one renal artery for each kidney with \u22654 mm diameter and with \u226520 mm treatable length\n             prior to a significant arterial branch (NOTE: All renal arteries with \u22654 mm diameter\n             and with \u226520 mm treatable length should be treated, including dual renal arteries\n             meeting these morphologic criteria.).  b) Renal artery stenosis (>50%) or renal\n             artery aneurysm in either renal artery.  c) A history of prior renal artery\n             intervention including balloon angioplasty or stenting. d) Renal arteries which\n             contain calcification which does not allow at least four radio frequency ablations to\n             be delivered. e) Diffuse fibromuscular dysplasia (FMD) or FMD which does not allow at\n             least four radio frequency ablations to be delivered; FMD defined as visible beading\n             of the artery on angiography. f) Unilateral kidney.\n\n          -  Estimated Glomerular Filtration Rate of <30 mL/min/1.73m2.\n\n          -  Primary pulmonary hypertension.\n\n          -  Pheochromocytoma, Cushing's Disease, coarctation of the aorta, untreated\n             hyperthyroidism, primary hyperparathyroidism or hyperaldosteronism (Note:  treated\n             hyperthyroidism is permissible).\n\n          -  Myocardial infarction, unstable angina pectoris, syncope, PCI/PTCA, or coronary\n             artery stenting within 3 months prior to signing the consent form, or has widespread\n             atherosclerosis with documented intravascular thrombosis or unstable plaques.\n\n          -  Cerebrovascular accident or TIA within 1 month prior to signing the consent form.\n\n          -  Prior ablation for atrial fibrillation in the left atrium.\n\n          -  Presence of a permanent pacemaker, biventricular pacemaker, loop recorder, atrial\n             defibrillator or any type of implantable cardiac defibrillator (with or without\n             biventricular pacing function).\n\n          -  Cardiac valve stenosis for which a significant reduction of blood pressure is\n             contraindicated.\n\n          -  A condition that would prohibit or interfere with ability to obtain an accurate blood\n             pressure measurement using the protocol-specified automatic blood pressure monitor\n             (e.g., arm diameter too large for the cuff).\n\n          -  Serious medical condition, which may adversely affect the safety and/or effectiveness\n             of the participant or the trial (e.g., patients with clinically significant\n             peripheral vascular disease, abdominal aortic aneurysm, bleeding disorders such as\n             thrombocytopenia, hemophilia, or significant anemia).\n\n          -  Pregnant, nursing or planning to be pregnant. (Female participants of childbearing\n             potential must have a negative serum or urine human chorionic gonadotropin (hCG)\n             pregnancy test prior to angiography).\n\n          -  Known history of drug use or alcohol dependency, lacks the ability to comprehend or\n             follow instructions, or would be unlikely or unable to comply with study follow-up\n             requirements.\n\n          -  Previous organ transplant.\n\n          -  Currently enrolled or plans to participate in a potentially confounding drug or\n             device trial during the course of this study.  Co-enrollment in concurrent studies is\n             allowed when documented pre-approval is obtained from the Medtronic study manager."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "265", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 13, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02064764", 
            "org_study_id": "Symplicity AF"
        }, 
        "intervention": [
            {
                "arm_group_label": "Cryoablation and renal nerve denervation", 
                "intervention_name": "Renal nerve denervation", 
                "intervention_type": "Drug", 
                "other_name": "Symplicity\u2122 Renal Denervation System"
            }, 
            {
                "arm_group_label": [
                    "Cryoablation only", 
                    "Cryoablation and renal nerve denervation"
                ], 
                "intervention_name": "Cryoablation", 
                "intervention_type": "Device", 
                "other_name": "Arctic Front Advance\u2122 Cardiac Cryoablation System"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "February 13, 2014", 
        "number_of_arms": "2", 
        "official_title": "Renal Nerve Denervation in Patients With Hypertension and Paroxysmal Atrial Fibrillation", 
        "overall_contact": {
            "email": "dana.wigert@medtronic.com", 
            "last_name": "Dana Wigert", 
            "phone": "763-526-2802"
        }, 
        "overall_contact_backup": {
            "email": "william.c.prather@medtronic.com", 
            "last_name": "William Prather", 
            "phone": "763-514-9897"
        }, 
        "overall_official": {
            "affiliation": "New York University Langone Medical Center", 
            "last_name": "Larry Chinitz, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "The objective characterizes the rate of safety composite events, adjudicated as a serious adverse event, within each of the two study arms and also characterizes the difference in the rates between study arms.  Each event in the composite has its own time frame, either one month or six months post procedure.", 
                "measure": "Safety composite events", 
                "safety_issue": "No", 
                "time_frame": "Up to one or six months post procedure depending on the event"
            }, 
            {
                "description": "Chronic treatment success is freedom from chronic treatment failure.  Chronic treatment failure is defined as the occurrence of either a documented episode of AF lasting 30 seconds or longer or an intervention for AF.", 
                "measure": "Rate of chronic treatment success between study arms", 
                "safety_issue": "No", 
                "time_frame": "Minimum of six months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02064764"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Medtronic Atrial Fibrillation Solutions", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Medtronic Atrial Fibrillation Solutions", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}